Advertisement

Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment

Published:August 27, 2016DOI:https://doi.org/10.1016/j.jtho.2016.08.138

      Abstract

      Squamous cell lung cancer (sqCLC) is an aggressive form of cancer that poses many therapeutic challenges. Patients tend to be older, present at a later stage, and have a high incidence of comorbidities, which can compromise treatment delivery and exacerbate toxicity. In addition, certain agents routinely available for nonsquamous cell histologic subtypes, such as bevacizumab and pemetrexed, are contraindicated or lack efficacy in sqCLC. Therapeutic progress has been much slower for advanced sqCLC, with median survival times of approximately 9 to 11 months in most studies. Herein, we discuss the current therapeutic landscape for patients with sqCLC versus with nonsquamous NSCLC. Current evidence indicates that new targeted treatments, notably monoclonal antibodies such as ramucirumab and necitumumab, and immunotherapies such as nivolumab and pembrolizumab can provide survival prolongation, although the benefits are still relatively modest. These incremental improvements, all realized since 2012, in aggregate, will very likely have a clinically meaningful impact for patients with sqCLC. We also discuss recent genomic studies of sqCLC that have identified potentially actionable molecular targets, as well as the relevant targeted agents in clinical development. Finally, we discuss the magnitude of survival benefit and the risk-to-benefit ratio that would prove clinically meaningful in this underserved patient population with unmet needs.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Thoracic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. American Cancer Society. What is non-small cell lung cancer? http://www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-what-is-non-small-cell-lung-cancer. Accessed July 5, 2016.

        • Youlden D.R.
        • Cramb S.M.
        • Baade P.D.
        The international epidemiology of lung cancer: geographical distribution and secular trends.
        J Thorac Oncol. 2008; 3: 819-831
        • Subramanian J.
        • Morgensztern D.
        • Goodgame B.
        • et al.
        Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis.
        J Thorac Oncol. 2010; 5: 23-28
        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2015.
        CA Cancer J Clin. 2015; 65: 5-29
        • Nichols L.
        • Saunders R.
        • Knollmann F.D.
        Causes of death of patients with lung cancer.
        Arch Pathol Lab Med. 2012; 136: 1552-1557
        • Pesch B.
        • Kendzia B.
        • Gustavsson P.
        • et al.
        Cigarette smoking and lung cancer—relative risk estimates for the major histological types from a pooled analysis of case-control studies.
        Int J Cancer. 2012; 131: 1210-1219
        • Papi A.
        • Casoni G.
        • Caramori G.
        • et al.
        COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma.
        Thorax. 2004; 59: 679-681
        • Janssen-Heijnen M.L.
        • Schipper R.M.
        • Razenberg P.P.
        • et al.
        Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study.
        Lung Cancer. 1998; 21: 105-113
        • Søgaard M.
        • Thomsen R.W.
        • Bossen K.S.
        • et al.
        The impact of comorbidity on cancer survival: a review.
        Clin Epidemiol. 2013; 5: 3-29
        • Asmis T.R.
        • Ding K.
        • Seymour L.
        • et al.
        Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials.
        J Clin Oncol. 2008; 26: 54-59
        • Putila J.
        • Guo N.L.
        Combining COPD with clinical, pathological and demographic information refines prognosis and treatment response prediction of non-small cell lung cancer.
        PLoS One. 2014; 9: e100994
        • Grønberg B.H.
        • Sundstrøm S.
        • Kaasa S.
        • et al.
        Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.
        Eur J Cancer. 2010; 46: 2225-2234
        • Ritzwoller D.P.
        • Carroll N.M.
        • Delate T.
        • et al.
        Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the Cancer Research Network.
        Lung Cancer. 2012; 78: 245-252
        • Lewis D.R.
        • Check D.P.
        • Caporaso N.E.
        • et al.
        US lung cancer trends by histologic type.
        Cancer. 2014; 120: 2883-2892
        • Lortet-Tieulent J.
        • Soerjomataram I.
        • Ferlay J.
        • et al.
        International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women.
        Lung Cancer. 2014; 84: 13-22
        • Janssen-Heijnen M.L.
        • Coebergh J.W.
        The changing epidemiology of lung cancer in Europe.
        Lung Cancer. 2003; 41: 245-258
        • Novaes F.T.
        • Cataneo D.C.
        • Ruiz Junior R.L.
        • et al.
        Lung cancer: histology, staging, treatment and survival.
        J Bras Pneumol. 2008; 34: 595-600
        • Fajraoui N.
        • Charfi M.R.
        • Khouani H.
        • et al.
        [Clinical epidemiology of primary lung cancer in Tunisia. 100 cases].
        Tunis Med. 2007; 85 ([in French]): 766-772
        • Salim E.I.
        • Jazieh A.R.
        • Moore M.A.
        Lung cancer incidence in the Arab league countries: risk factors and control.
        Asian Pac J Cancer Prev. 2011; 12: 17-34
        • Morgensztern D.
        • Waqar S.
        • Subramanian J.
        • et al.
        Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005.
        J Thorac Oncol. 2009; 4: 1524-1529
        • Cancer Genome Atlas Research Network
        Comprehensive genomic characterization of squamous cell lung cancers.
        Nature. 2012; 489: 519-525
        • Kris M.G.
        • Johnson B.E.
        • Berry L.D.
        • et al.
        Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
        JAMA. 2014; 311: 1998-2006
        • Paik P.K.
        • Hasanovic A.
        • Wang L.
        • et al.
        Multiplex testing for driver mutations in squamous cell carcinomas of the lung.
        J Clin Oncol. 2012; 30 ([abstract]): 7505
        • Pan Y.
        • Wang R.
        • Ye T.
        • et al.
        Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.
        Chest. 2014; 145: 473-479
        • König K.
        • Peifer M.
        • Fassunke J.
        • et al.
        Implementation of amplicon parallel sequencing leads to improvement of diagnosis and therapy of lung cancer patients.
        J Thorac Oncol. 2015; 10: 1049-1057
      2. European Medicines Agency. Assessment report for Erbitux. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/000558/WC500075683.pdf. Accessed July 5, 2016.

        • Johnson D.H.
        • Fehrenbacher L.
        • Novotny W.F.
        • et al.
        Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
        J Clin Oncol. 2004; 22: 2184-2191
        • Langer C.J.
        • Novello S.
        • Park K.
        • et al.
        Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer.
        J Clin Oncol. 2014; 32: 2059-2066
        • Scagliotti G.
        • Novello S.
        • von Pawel J.
        • et al.
        Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
        J Clin Oncol. 2010; 28: 1835-1842
        • Scagliotti G.V.
        • Vynnychenko I.
        • Park K.
        • et al.
        International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.
        J Clin Oncol. 2012; 30: 2829-2836
        • Novello S.
        • Scagliotti G.V.
        • Sydorenko O.
        • et al.
        Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.
        J Thorac Oncol. 2014; 9: 1154-1161
      3. Sanofi. Sanofi provides update on phase 3 studies of two investigational compounds. http://en.sanofi.com/Images/33127_20130603_rdupdate_en.pdf. Accessed July 5, 2016.

      4. US Food and Drug Administration. Portrazza. Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125547s000lbl.pdf. Accessed July 5, 2016.

        • Scagliotti G.V.
        • Parikh P.
        • von Pawel J.
        • et al.
        Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
        J Clin Oncol. 2008; 26: 3543-3551
        • Socinski M.A.
        • Bondarenko I.
        • Karaseva N.A.
        • et al.
        Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
        J Clin Oncol. 2012; 30: 2055-2062
        • Paz-Ares L.G.
        • de Marinis F.
        • Dediu M.
        • et al.
        PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
        J Clin Oncol. 2013; 31: 2895-2902
        • Sandler A.
        • Gray R.
        • Perry M.C.
        • et al.
        Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
        N Engl J Med. 2006; 355: 2542-2550
        • Sandler A.
        • Yi J.
        • Dahlberg S.
        • et al.
        Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer.
        J Thorac Oncol. 2010; 5: 1416-1423
        • Bonomi P.D.
        • Finkelstein D.M.
        • Ruckdeschel J.C.
        • et al.
        Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
        J Clin Oncol. 1989; 7: 1602-1613
        • Fossella F.
        • Pereira J.R.
        • von Pawel J.
        • et al.
        Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
        J Clin Oncol. 2003; 21: 3016-3024
        • Rosell R.
        • Gatzemeier U.
        • Betticher D.C.
        • et al.
        Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial.
        Ann Oncol. 2002; 13: 1539-1549
        • Schiller J.H.
        • Harrington D.
        • Belani C.P.
        • et al.
        Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
        N Engl J Med. 2002; 346: 92-98
        • Sandler A.B.
        • Nemunaitis J.
        • Denham C.
        • et al.
        Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
        J Clin Oncol. 2000; 18: 122-130
        • Wozniak A.J.
        • Crowley J.J.
        • Balcerzak S.P.
        • et al.
        Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.
        J Clin Oncol. 1998; 16: 2459-2465
        • Hoang T.
        • Dahlberg S.E.
        • Schiller J.H.
        • et al.
        Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
        Lung Cancer. 2013; 81: 47-52
        • Kelly K.
        • Chansky K.
        • Mack P.C.
        • et al.
        Chemotherapy outcomes by histologic subtypes of non–small-cell lung cancer: analysis of the Southwest Oncology Group database for antimicrotubule-platinum therapy.
        Clin Lung Cancer. 2013; 14: 627-635
        • Lilenbaum R.C.
        • Herndon II, J.E.
        • List M.A.
        • et al.
        Single-agent versus combination chemotherapy in advanced non–small-cell lung cancer: the Cancer and Leukemia Group B (study 9730).
        J Clin Oncol. 2005; 23: 190-196
        • Tan E.H.
        • Rolski J.
        • Grodzki T.
        • et al.
        Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer.
        Ann Oncol. 2009; 20: 1249-1256
        • Shukuya T.
        • Yamanaka T.
        • Seto T.
        • et al.
        Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2015; 16: 1630-1638
        • Scagliotti G.
        • Hanna N.
        • Fossella F.
        • et al.
        The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies.
        Oncologist. 2009; 14: 253-263
        • Garassino M.C.
        • Martelli O.
        • Broggini M.
        • et al.
        Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
        Lancet Oncol. 2013; 14: 981-988
        • Karampeazis A.
        • Voutsina A.
        • Souglakos J.
        • et al.
        Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
        Cancer. 2013; 119: 2754-2764
        • Shepherd F.A.
        • Dancey J.
        • Ramlau R.
        • et al.
        Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
        J Clin Oncol. 2000; 18: 2095-2103
        • Shepherd F.A.
        • Rodrigues Pereira J.
        • Ciuleanu T.
        • et al.
        Erlotinib in previously treated non-small-cell lung cancer.
        N Engl J Med. 2005; 353: 123-132
        • Marino P.
        • Pampallona S.
        • Preatoni A.
        • et al.
        Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature.
        Chest. 1994; 106: 861-865
        • Delbaldo C.
        • Michiels S.
        • Syz N.
        • et al.
        Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis.
        JAMA. 2004; 292: 470-484
        • Alberola V.
        • Camps C.
        • Provencio M.
        • et al.
        Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
        J Clin Oncol. 2003; 21: 3207-3213
        • Ciuleanu T.
        • Brodowicz T.
        • Zielinski C.
        • et al.
        Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
        Lancet. 2009; 374: 1432-1440
        • Fukuoka M.
        • Wu Y.L.
        • Thongprasert S.
        • et al.
        Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
        J Clin Oncol. 2011; 29: 2866-2874
        • Mok T.S.
        • Wu Y.L.
        • Thongprasert S.
        • et al.
        Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
        N Engl J Med. 2009; 361: 947-957
        • Rosell R.
        • Carcereny E.
        • Gervais R.
        • et al.
        Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
        Lancet Oncol. 2012; 13: 239-246
        • Haaland B.
        • Tan P.S.
        • de Castro Jr., G.
        • et al.
        Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.
        J Thorac Oncol. 2014; 9: 805-811
        • Sequist L.V.
        • Yang J.C.H.
        • Yamamoto N.
        • et al.
        Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.
        J Clin Oncol. 2013; 31: 3327-3334
        • Solomon B.J.
        • Mok T.
        • Kim D.W.
        • et al.
        First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
        N Engl J Med. 2014; 371: 2167-2177
        • Wu Y.L.
        • Zhou C.
        • Hu C.P.
        • et al.
        Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
        Lancet Oncol. 2014; 15: 213-222
        • Leighl N.B.
        • Rekhtman N.
        • Biermann W.A.
        • et al.
        Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guideline.
        J Clin Oncol. 2014; 32: 3673-3679
        • Lindeman N.I.
        • Cagle P.T.
        • Beasley M.B.
        • et al.
        Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors. Guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
        J Thorac Oncol. 2013; 8: 823-859
      5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines): non-small cell lung cancer. Version 4.2016. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed July 5, 2016.

        • Reck M.
        • Popat S.
        • Reinmuth N.
        • et al.
        Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2014; 25: iii27-iii39
        • Yang J.C.
        • Wu Y.L.
        • Schuler M.
        • et al.
        Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
        Lancet Oncol. 2015; 16: 141-151
        • Shaw A.T.
        • Yeap B.Y.
        • Solomon B.J.
        • et al.
        Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
        Lancet Oncol. 2011; 12: 1004-1012
        • Takano T.
        • Fukui T.
        • Ohe Y.
        • et al.
        EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
        J Clin Oncol. 2008; 26: 5589-5595
      6. European Medicines Agency. Avastin summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000582/WC500029271.pdf. Accessed July 5, 2016.

      7. US Food and Drug Administration. Avastin. Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125085s312lbl.pdf. Accessed July 5, 2016.

        • Davis K.L.
        • Goyal R.K.
        • Able S.L.
        • et al.
        Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
        Lung Cancer. 2015; 87: 176-185
        • Leighl N.B.
        Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line.
        Curr Oncol. 2012; 19: S52-S58
        • Shi Y.
        • Sun Y.
        Medical management of lung cancer: experience in China.
        Thoracic Cancer. 2015; 6: 10-16
        • Ameratunga M.
        • Pavlakis N.
        • Gebski V.
        • et al.
        Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.
        Asia Pac J Clin Oncol. 2014; 10: 273-278
        • Hanna N.
        • Shepherd F.A.
        • Fossella F.V.
        • et al.
        Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
        J Clin Oncol. 2004; 22: 1589-1597
        • Aerts J.G.
        • Codrington H.
        • Lankheet N.A.
        • et al.
        A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study.
        Ann Oncol. 2013; 24: 2860-2865
        • Gebbia V.
        • Gridelli C.
        • Verusio C.
        • et al.
        Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial.
        Lung Cancer. 2009; 63: 251-258
        • Nelli F.
        • Naso G.
        • De Pasquale Ceratti A.
        • et al.
        Weekly vinorelbine and docetaxel as second-line chemotherapy for pretreated non-small cell lung cancer patients: a phase I-II trial.
        J Chemother. 2004; 16: 392-399
        • Takeda K.
        • Negoro S.
        • Tamura T.
        • et al.
        Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104).
        Ann Oncol. 2009; 20: 835-841
        • William Jr., W.N.
        • Khuri F.R.
        • Fossella F.V.
        • et al.
        Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.
        Am J Clin Oncol. 2010; 33: 148-152
        • Kim E.S.
        • Neubauer M.
        • Cohn A.
        • et al.
        Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
        Lancet Oncol. 2013; 14: 1326-1336
        • Ramlau R.
        • Gorbunova V.
        • Ciuleanu T.E.
        • et al.
        Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial.
        J Clin Oncol. 2012; 30: 3640-3647
      8. US Food and Drug Administration. Alimta. Approval package for application number: 21–462/S-015. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021462s015.pdf. Accessed July 5, 2016.

        • Okano Y.
        • Ando M.
        • Asami K.
        • et al.
        Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
        J Clin Oncol. 2013; 31 ([abstract]): 8006
        • Kim E.S.
        • Hirsh V.
        • Mok T.
        • et al.
        Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
        Lancet. 2008; 372: 1809-1818
      9. European Medicines Agency. Cyramza summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002829/WC500180724.pdf. Accessed July 5, 2016.

      10. US Food and Drug Administration. Cyramza. Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125477s011lbl.pdf. Accessed July 5, 2016.

        • Garon E.B.
        • Ciuleanu T.E.
        • Arrieta O.
        • et al.
        Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
        Lancet. 2014; 384: 665-673
        • Hirsch F.R.
        • Varella-Garcia M.
        • Bunn Jr., P.A.
        • et al.
        Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
        J Clin Oncol. 2003; 21: 3798-3807
        • Pirker R.
        • Pereira J.R.
        • Szczesna A.
        • et al.
        Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
        Lancet. 2009; 373: 1525-1531
        • Pujol J.L.
        • Pirker R.
        • Lynch T.J.
        • et al.
        Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer.
        Lung Cancer. 2014; 83: 211-218
        • Hirsch F.R.
        • Herbst R.S.
        • Olsen C.
        • et al.
        Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
        J Clin Oncol. 2008; 26: 3351-3357
        • Khambata-Ford S.
        • Harbison C.T.
        • Hart L.L.
        • et al.
        Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
        J Clin Oncol. 2010; 28: 918-927
        • Lynch T.J.
        • Patel T.
        • Dreisbach L.
        • et al.
        Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
        J Clin Oncol. 2010; 28: 911-917
        • Pirker R.
        • Pereira J.R.
        • von Pawel J.
        • et al.
        EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
        Lancet Oncol. 2012; 13: 33-42
        • Thatcher N.
        • Hirsch F.R.
        • Luft A.V.
        • et al.
        Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
        Lancet Oncol. 2015; 16: 763-774
      11. S0819: carboplatin/paclitaxel with or without bevacizumab and/or cetuximab with stage IV or recurrent non-small cell lung cancer. https://www.clinicaltrials.gov/ct2/show/NCT00946712. Accessed July 5, 2016.

        • Redman M.W.
        • Crowley J.J.
        • Herbst R.S.
        • et al.
        Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819.
        Clin Cancer Res. 2012; 18: 4004-4012
      12. Herbst R, Redman M, Kim ES, et al. A randomized, phase III study comparing carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC): SWOG S0819. Abstract PLEN04.01 presented at: 16th World Conference on Lung Cancer. September 6–9, 2015; Denver, CO.

      13. Hirsch FR, Boyle TA, Thatcher N, et al. EGFR IHC and FISH correlative analyses (SQUIRE trial): necitumumab + gemcitabine-cisplatin vs gemcitabine-cisplatin in 1st-line squamous NSCLC [abstract]. Abstract ORAL32.05 presented at: 16th World Conference on Lung Cancer. September 6–9, 2015; Denver, CO.

      14. European Medicines Agency. Portrazza summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003886/WC500202694.pdf. Accessed July 5, 2016.

        • Soria J.C.
        • Felip E.
        • Cobo M.
        • et al.
        Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
        Lancet Oncol. 2015; 16: 897-907
      15. US Food and Drug Administration. Gilotrif. Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201292s009lbl.pdf. Accessed July 5, 2016.

      16. European Medicines Agency. Giotrif summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002280/WC500152392.pdf. Accessed July 5, 2016.

        • Davies M.
        New modalities of cancer treatment for NSCLC: focus on immunotherapy.
        Cancer Manag Res. 2014; 6: 63-75
        • Lynch T.J.
        • Bondarenko I.
        • Luft A.
        • et al.
        Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.
        J Clin Oncol. 2012; 30: 2046-2054
        • Lynch T.
        • Bondarenko I.
        • Luft A.
        • et al.
        Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in non-small cell lung cancer: analysis by baseline histology in a phase 2 trial.
        J Thorac Oncol. 2011; 6 ([abstract]): S660
        • Brahmer J.
        • Reckamp K.L.
        • Baas P.
        • et al.
        Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.
        N Engl J Med. 2015; 373: 123-135
        • Garon E.B.
        • Rizvi N.A.
        • Hui R.
        • et al.
        Pembrolizumab for the treatment of non-small-cell lung cancer.
        N Engl J Med. 2015; 372: 2018-2028
      17. Soria JC, Fløtten Ø, Horn L, et al. Efficacy and safety of pembrolizumab (pembro; MK-3475) for patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC) enrolled in KEYNOTE-001. Abstract 33LBA presented at: European Cancer Congress 2015. September 25–29, 2015; Vienna, Austria.

      18. US Food and Drug Administration. Keytruda. Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125514s004s006lbl.pdf. Accessed July 5, 2016.

        • Herbst R.S.
        • Baas P.
        • Kim D.W.
        • et al.
        Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
        Lancet. 2016; 387: 1540-1550
        • Rizvi N.
        • Chow L.Q.M.
        • Dirix L.Y.
        • et al.
        Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC).
        J Clin Oncol. 2014; 32 ([abstract]): TPS8123
        • Ramalingam S.S.
        • Mazières J.
        • Planchard D.
        • et al.
        Phase II study of nivolumab (anti PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancer.
        Int J Radiat Oncol Biol Phys. 2014; 90 ([abstract]): 1266
      19. Horn L, Herbst RS, Spigel D, et al. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1). Abstract MO18.01 presented at: the 15th World Conference on Lung Cancer. October 27–30, 2013; Sydney, Australia.

        • Rizvi N.A.
        • Hellmann M.D.
        • Snyder A.
        • et al.
        Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
        Science. 2015; 348: 124-128
        • Pao W.
        • Hutchinson K.E.
        Chipping away at the lung cancer genome.
        Nat Med. 2012; 18: 349-351
        • Sos M.L.
        • Thomas R.K.
        Genetic insight and therapeutic targets in squamous-cell lung cancer.
        Oncogene. 2012; 31: 4811-4814
        • Weiss J.
        • Sos M.L.
        • Seidel D.
        • et al.
        Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous-cell lung cancer.
        Sci Transl Med. 2010; 2 (62ra93)
        • Hammerman P.S.
        • Sos M.L.
        • Ramos A.H.
        • et al.
        Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
        Cancer Discov. 2011; 1: 78-89
        • Shtivelman E.
        • Hensing T.
        • Simon G.R.
        • et al.
        Molecular pathways and therapeutic targets in lung cancer.
        Oncotarget. 2014; 5: 1392-1433
        • Heist R.S.
        • Mino-Kenudson M.
        • Sequist L.V.
        • et al.
        FGFR1 amplification in squamous cell carcinoma of the lung.
        J Thorac Oncol. 2012; 7: 1775-1780
        • Gadgeel S.M.
        • Chen W.
        • Cote M.L.
        • et al.
        Fibroblast growth factor receptor 1 amplification in non-small cell lung cancer by quantitative real-time PCR.
        PLoS One. 2013; 8: e79820
        • Yamamoto H.
        • Shigematsu H.
        • Nomura M.
        • et al.
        PIK3CA mutations and copy number gains in human lung cancers.
        Cancer Res. 2008; 68: 6913-6921
        • Miao L.
        • Wang Y.
        • Zhu S.
        • et al.
        Identification of novel driver mutations of the discoidin domain receptor 2 (DDR2) gene in squamous cell lung cancer of Chinese patients.
        BMC Cancer. 2014; 14: 369
        • Liao R.G.
        • Watanabe H.
        • Meyerson M.
        • et al.
        Targeted therapy for squamous cell lung cancer.
        Lung Cancer Manag. 2012; 1: 293-300
        • Brunner A.M.
        • Costa D.B.
        • Heist R.S.
        • et al.
        Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.
        J Thorac Oncol. 2013; 8: 1434-1437
        • Goss G.
        • Felip E.
        • Cobo M.
        • et al.
        A randomized, open-label, phase III trial of Afatinib (A) vs erlotinib (E) as second-line treatment of patients (PTS) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: LUX-Lung 8 (LL8).
        Ann Oncol. 2014; 25 ([abstract]): iv426
        • Paik P.K.
        • Shen R.
        • Ferry D.
        • et al.
        A phase 1b open-label multicenter study of AZD4547 in patients with advanced squamous cell lung cancers: Preliminary antitumour activity and pharmacodynamic data.
        J Clin Oncol. 2014; 32 ([abstract]): 8035
        • Soria J.-C.
        • Vansteenkiste J.F.
        • Canon J.
        • et al.
        Buparlisib (BKM120) in patients with PI3K pathway-activated, metastatic non-small cell lung cancer (NSCLC): results from the BASALT-1 study.
        Ann Oncol. 2014; 25 ([abstract]): iv426
      20. Lung Cancer Master Protocol (Lung-MAP) Clinical Trials. Lung-MAP. http://lung-map.org/. Accessed July 5, 2016.

        • Ellis L.M.
        • Bernstein D.S.
        • Voest E.E.
        • et al.
        American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes.
        J Clin Oncol. 2014; 32: 1277-1280
        • Nadpara P.A.
        • Madhavan S.S.
        • Tworek C.
        • et al.
        Guideline-concordant lung cancer care and associated health outcomes among elderly patients in the United States.
        J Geriatr Oncol. 2015; 6: 101-110
        • Salloum R.G.
        • Smith T.J.
        • Jensen G.A.
        • et al.
        Factors associated with adherence to chemotherapy guidelines in patients with non-small cell lung cancer.
        Lung Cancer. 2012; 75: 255-260